Neurodegeneration and neuroprotection in Parkinson's Disease / edited by C.W. Olanow, Peter Jenner, Moussa Youdim.Material type: TextSeries: Neuroscience perspectivesPublication details: London : Academic Press, 1996.ISBN:
- 616.833 20
|Two Week Loan
|College Lane Learning Resources Centre Main Shelves
|616.833 OLA (Browse shelf(Opens below))
Enhanced descriptions from Syndetics:
1. Oxidative stress, brain iron and neurodegeneration. Basic principles / J. M. C. Gutteridge and B. Halliwell -- 2. Pathological evidence for oxidative stress in Parkinson's disease and related degenerative disorders / P. Jenner and C. W. Olanow -- 3. Treatment of Parkinson's disease with deprenyl (selegiline) and other monoamine oxidase inhibitors / K. Kieburtz and J. Shoulson -- 4. Iron and neurodegeneration: prospects for neuroprotection / C. W. Olanow and M. B. H. Youdim -- 5. Nitrone radical traps protect in experimental neurodegenerative diseases / R. A. Floyd and J. M. Carney -- 6. Therapeutic effects of nitric oxide synthase inhibition in neuronal injury / M. Flint Beal -- 7. Mitochondrial dysfunction in neurodegeneration: prospects for neuroprotection / A. H. V. Schapira -- 8. Bioenergetics and excitotoxicity: the weak excitotoxic hypothesis / J. G. Greene and J. T. Greenamyre -- 9. Calcium ions in necrotic and apoptotic cell death / P. Nicotera and S. Orrenius -- 10. Neurotrophic factors: towards a restorative therapy of Parkinson's disease / C. A. Altar, S. J. Wiegand, R. M. Lindsay and J. M. Cedarbaum -- 11. Immune-mediated cell death and neuroprotection in neurodegenerative diseases / S. H. Appel, R. G. Smith and W. D. Le -- 12. Reduction of neuronal apoptosis by small molecules: promise for new approaches to neurological therapy / W. G. Tatton, W. Y. H. Ju, J. Wadia and N. A. Tatton.
Parkinson's disease (PD) is an age-related neurodegenerative disorder characterized by a relatively selective degeneration of dopaminergic neurons, a loss of striatal dopamine, and intracellular inclusions. Current treatment consists of a dopamine replacement strategy, primarily using the dopamine precursor levodopa. However the majority of patients experience intolerable drug-related side effects, an unacceptable level of disability, and an increased mortality rate. Accordingly, there has been intense interest in the development of a 'neuroprotective therapy' that can prevent neuronal degeneration and slow or stop disease progression. It is likely that a cascade of events involving free radicals and oxidative stress, mitochondrial dysfunction with a bioenergetic impairment, excitotoxicity, and a rise in intracytoplasmic free calcium with activation of biodestructive enzymes contributes to the neurodegenerative process. There is also interest in the role of apoptotic cell death in neurodegeneration and the possibility that some small molecules can provide neuroprotection or neuronal rescue by upregulating cellular defenses through the induction of translational changes and new protein synthesis. This is the first book to comprehensive review the factors implicated in the pathogenesis of cell death in PD. Each chapter of this book examines a different factor and considers the evidence supporting its participation in the neurodegenerative process and specific strategies based on this mechanism that might lead to neuroprotection.